The metabolic syndrome in cancer survivors

The Lancet Oncology

Volumn 11, Issue 2, 2010, Pages 193-203

  de Haas, Esther C ^a   Oosting, Sjoukje F ^a   Lefrandt, Joop D ^a   Wolffenbuttel, Bruce HR ^a   Sleijfer, Dirk Th ^a   Gietema, Jourik A ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GROWTH HORMONE; METFORMIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PLACEBO; TESTOSTERONE; UNCLASSIFIED DRUG;

CANCER SURVIVOR; CANCER THERAPY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DYSLIPIDEMIA; HUMAN; HYPERGLYCEMIA; METABOLIC SYNDROME X; PATHOPHYSIOLOGY; PATIENT IDENTIFICATION; PREVALENCE; PRIORITY JOURNAL; REVIEW;

HUMANS; METABOLIC SYNDROME X; NEOPLASMS; PREVALENCE; SURVIVORS;

EID: 75249096859     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(09)70287-6     Document Type: Review

References (86)

1. Verdecchia A., Francisci S., Brenner H., et al. Recent cancer survival in Europe: a 2000-02 period analysis of EUROCARE-4 data. Lancet Oncol 8 (2007) 784-796
2. Gatta G., Zigon G., Capocaccia R., et al. Survival of European children and young adults with cancer diagnosed 1995-2002. Eur J Cancer 45 (2009) 992-1005
3. Oeffinger K.C., Mertens A.C., Sklar C.A., et al. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med 355 (2006) 1572-1582
4. Fossa S.D., Vassilopoulou-Sellin R., and Dahl A.A. Long term physical sequelae after adult-onset cancer. J Cancer Surviv 2 (2008) 3-11
5. Nuver J., Smit A.J., Sleijfer D., et al. Microalbuminuria, decreased fibrinolysis, and inflammation as early signs of atherosclerosis in long-term survivors of disseminated testicular cancer. Eur J Cancer 40 (2004) 701-706
6. Talvensaari K.K., Lanning M., Tapanainen P., and Knip M. Long-term survivors of childhood cancer have an increased risk of manifesting the metabolic syndrome. J Clin Endocrinol Metab 81 (1996) 3051-3055
7. Meinardi M.T., Gietema J.A., van der Graaf W., et al. Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. J Clin Oncol 18 (2000) 1725-1732
8. Reaven G.M. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 37 (1988) 1595-1607
9. Eckel R.H., Grundy S.M., and Zimmet P.Z. The metabolic syndrome. Lancet 365 (2005) 1415-1428
10. World Health Organization. Definition, diagnosis, and classification of diabetes mellitus and its complications: report of a WHO consultation. Part 1: diagnosis and classification of diabetes mellitus (1999), World Health Organization, Geneva
11. Balkau B., and Charles M.A. Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet Med 16 (1999) 442-443
12. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
13. Einhorn D., Reaven G.M., Cobin R.H., et al. American College of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract 9 (2003) 237-252
14. Grundy S.M., Cleeman J.I., Daniels S.R., et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation 112 (2005) 2735-2752
15. Alberti K.G., Zimmet P., and Shaw J. Metabolic syndrome-a new world-wide definition: a consensus statement from the International Diabetes Federation. Diabet Med 23 (2006) 469-480
16. Després J.P., and Lemieux I. Abdominal obesity and metabolic syndrome. Nature 444 (2006) 881-887
17. Grundy S.M. Metabolic syndrome pandemic. Arterioscler Thromb Vasc Biol 28 (2008) 629-636
18. Gami A.S., Witt B.J., Howard D.E., et al. Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol 49 (2007) 403-414
19. Kahn R., Buse J., Ferrannini E., and Stern M. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 28 (2005) 2289-2304
20. Sattar N., McConnachie A., Shaper A.G., et al. Can metabolic syndrome usefully predict cardiovascular disease and diabetes? Outcome data from two prospective studies. Lancet 371 (2008) 1927-1935
21. Calle E.E., and Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 4 (2004) 579-591
22. Cowey S., and Hardy R.W. The metabolic syndrome: a high-risk state for cancer?. Am J Pathol 169 (2006) 1505-1522
23. Stocks T., Lukanova A., Johansson M., et al. Components of the metabolic syndrome and colorectal cancer risk; a prospective study. Int J Obes 32 (2008) 304-314
24. Kabat G.C., Kim M., Chlebowski R.T., et al. A longitudinal study of the metabolic syndrome and risk of postmenopausal breast cancer. Cancer Epidemiol Biomarkers Prev 18 (2009) 2046-2053
25. Kourti M., Tragiannidis A., Makedou A., Papageorgiou T., Rousso I., and Athanassiadou F. Metabolic syndrome in children and adolescents with acute lymphoblastic leukemia after the completion of chemotherapy. J Pediatr Hematol Oncol 27 (2005) 499-501
26. Gurney J.G., Ness K.K., Sibley S.D., et al. Metabolic syndrome and growth hormone deficiency in adult survivors of childhood acute lymphoblastic leukemia. Cancer 107 (2006) 1303-1312
27. Follin C., Thilén U., Ahrén B., and Erfurth E.M. Improvement in cardiac systolic function and reduced prevalence of metabolic syndrome after two years of growth hormone (GH) treatment in GH-deficient adult survivors of childhood-onset acute lymphoblastic leukemia. J Clin Endocrinol Metab 91 (2006) 1872-1875
28. Trimis G., Moschovi M., Papassotiriou I., Chrousos G., and Tzortzatou-Stathopoulou F. Early indicators of dysmetabolic syndrome in young survivors of acute lymphoblastic leukemia in childhood as a target for preventing disease. J Pediatr Hematol Oncol 29 (2007) 309-314
29. Taskinen M., Lipsanen-Nyman M., Tiitinen A., Hovi L., and Saarinen-Pihkala U.M. Insufficient growth hormone secretion is associated with metabolic syndrome after allogeneic stem cell transplantation in childhood. J Pediatr Hematol Oncol 29 (2007) 529-534
30. Pietilä S., Mäkipernaa A., Sievanen H., Koivisto A.M., Wigren T., and Lenko H.L. Obesity and metabolic changes are common in young childhood brain tumor survivors. Pediatr Blood Cancer 52 (2009) 853-859
31. Hoffman K.E., Derdak J., Bernstein D., et al. Metabolic syndrome traits in long-term survivors of pediatric sarcoma. Pediatr Blood Cancer 50 (2008) 341-346
32. Nuver J., Smit A.J., Wolffenbuttel B.H.R., et al. The metabolic syndrome and disturbances in hormone levels in long-term survivors of disseminated testicular cancer. J Clin Oncol 23 (2005) 3718-3725
33. Haugnes H.S., Aass N., Fosså S.D., et al. Components of the metabolic syndrome in long-term survivors of testicular cancer. Ann Oncol 18 (2007) 241-248
34. Annaloro C., Usardi P., Airaghi L., et al. Prevalence of metabolic syndrome in long-term survivors of hematopoietic stem cell transplantation. Bone Marrow Transplant 41 (2008) 797-804
35. Majhail N.S., Flowers M.E., Ness K.K., et al. High prevalence of metabolic syndrome after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 43 (2009) 49-54
36. Braga-Basaria M., Dobs A.S., Muller D.C., et al. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol 24 (2006) 3979-3983
37. Darzy K.H., and Shalet S.M. Hypopituitarism following radiotherapy. Pituitary 12 (2009) 40-50
38. Molitch M.E., Clemmons D.R., Malozowski S., Merriam G.R., Shalet S.M., and Vance M.L. Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 91 (2006) 1621-1634
39. Oeffinger K.C., Mertens A.C., Sklar C.A., et al. Obesity in adult survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study. J Clin Oncol 21 (2003) 1359-1365
40. Gurney J.G., Ness K.K., Stovall M., et al. Final height and body mass index among adult survivors of childhood brain cancer: childhood cancer survivor study. J Clin Endocrinol Metab 88 (2003) 4731-4739
41. Meacham L.R., Gurney J.G., Mertens A.C., et al. Body mass index in long-term adult survivors of childhood cancer: a report of the childhood cancer survivor study. Cancer 103 (2005) 1730-1739
42. Janiszewski P.M., Oeffinger K.C., Church T.S., et al. Abdominal obesity, liver fat, and muscle composition in survivors of childhood acute lymphoblastic leukemia. J Clin Endocrinol Metab 92 (2007) 3816-3821
43. Haddy T.B., Mosher R.B., Nunez S.B., and Reaman G.H. Growth hormone deficiency after chemotherapy for acute lymphoblastic leukemia in children who have not received cranial radiation. Pediatr Blood Cancer 46 (2006) 258-261
44. Roos A., Bakker S.J.L., Links T.P., Gans R., and Wolffenbuttel B.H.R. Thyroid function is associated with components of the metabolic syndrome in euthyroid subjects. J Clin Endocrinol Metab 92 (2007) 491-496
45. Sklar C., Whitton J., Mertens A., et al. Abnormalities of the thyroid in survivors of Hodgkin's disease: data from the Childhood Cancer Survivor Study. J Clin Endocrinol Metab 85 (2000) 3227-3232
46. Mercado G., Adelstein D.J., Saxton J.P., Secic M., Larto M.A., and Lavertu P. Hypothyroidism: a frequent event after radiotherapy and after radiotherapy with chemotherapy for patients with head and neck carcinoma. Cancer 92 (2001) 2892-2897
47. Tell R., Lundell G., Nilsson B., Sjödin H., Lewin F., and Lewensohn R. Long-term incidence of hypothyroidism after radiotherapy in patients with head-and-neck cancer. Int J Radiat Oncol Biol Phys 60 (2004) 395-400
48. Sanders J.E., Hoffmeister P.A., Woolfrey A.E., et al. Thyroid function following hematopoietic cell transplantation in children: 30 years' experience. Blood 113 (2009) 306-308
49. Laaksonen D.E., Niskanen L., Punnonen K., et al. Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care 27 (2004) 1036-1041
50. Schmiegelow M., Lassen S., Poulsen H.S., et al. Gonadal status in male survivors following childhood brain tumors. J Clin Endocrinol Metab 86 (2001) 2446-2452
51. Howell S.J., Radford J.A., Adams J.E., and Shalet S.M. The impact of mild Leydig cell dysfunction following cytotoxic chemotherapy on bone mineral density (BMD) and body composition. Clin Endocrinol 52 (2000) 609-616
52. Smith J.C., Bennett S., Evans L.M., et al. The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. J Clin Endocrinol Metab 86 (2001) 4261-4267
53. Smith M.R., Lee H., McGovern F., et al. Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer: differences from the classic metabolic syndrome. Cancer 112 (2008) 2188-2194
54. Carr M.C. The emergence of the metabolic syndrome with menopause. J Clin Endocrinol Metab 88 (2003) 2404-2411
55. Dørum A., Tonstad S., Liavaag A.H., Michelsen T.M., Hildrum B., and Dahl A.A. Bilateral oophorectomy before 50 years of age is significantly associated with the metabolic syndrome and Framingham risk score: a controlled, population-based study (HUNT-2). Gynecol Oncol 109 (2008) 377-383
56. Green D.M., Sklar C.A., Boice Jr. J.D., et al. Ovarian failure and reproductive outcomes after childhood cancer treatment from the Childhood Cancer Survivor Study. J Clin Oncol 27 (2009) 2374-2381
57. Taskinen M., Saarinen-Pihkala U.M., Hovi L., and Lipsanen-Nyman M. Impaired glucose tolerance and dyslipidaemia as late effects after bone-marrow transplantation in childhood. Lancet 356 (2000) 993-997
58. Demark-Wahnefried W., Peterson B.L., Winer E.P., et al. Changes in weight, body composition, and factors influencing energy balance among premenopausal breast cancer patients receiving adjuvant chemotherapy. J Clin Oncol 19 (2001) 2381-2389
59. Vehmanen L., Saarto T., Blomqvist C., Taskinen M.R., and Elomaa I. Tamoxifen treatment reverses the adverse effects of chemotherapy-induced ovarian failure on serum lipids. Br J Cancer 91 (2004) 476-481
60. Lewis S. Do endocrine treatments for breast cancer have a negative impact on lipid profiles and cardiovascular risk in postmenopausal women?. Am Heart J 153 (2007) 182-188
61. Warner J.T., Bell W., Webb D.K.H., and Gregory J.W. Relationship between cardiopulmonary response to exercise and adiposity in survivors of childhood malignancy. Arch Dis Child 76 (1997) 298-303
62. Mayer E., Reuter M., Dopfer R.E., and Ranke M.B. Energy expenditure, energy intake and prevalence of obesity after therapy for acute lymphoblastic leukemia during childhood. Horm Res 53 (2000) 193-199
63. Brennan B.M.D., Rahim A., Blum W.F., Adams J.A., Eden O.B., and Shalet S.M. Hyperleptinaemia in young adults following cranial irradiation in childhood: growth hormone deficiency or leptin insensitivity?. Clin Endocrinol 50 (1999) 163-169
64. He K., Liu K., Daviglus M.L., et al. Magnesium intake and incidence of metabolic syndrome among young adults. Circulation 113 (2006) 1675-1682
65. Lajer H., Bundgaard H., Secher N.H., Hansen H.H., Kjeldsen K., and Daugaard G. Severe intracellular magnesium and potassium depletion in patients after treatment with cisplatin. Br J Cancer 89 (2003) 1633-1637
66. Huddart R.A., Norman A., Shahidi M., et al. Cardiovascular disease as a long-term complication of treatment for testicular cancer. J Clin Oncol 21 (2003) 1513-1523
67. Nuver J., Smit A.J., van der Meer J., et al. Acute chemotherapy-induced cardiovascular changes in patients with testicular cancer. J Clin Oncol 23 (2005) 9130-9137
68. Kim J.A., Montagnani M., Koh K.K., and Quon M.J. Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation 113 (2006) 1888-1904
69. Mancia G., Bousquet P., Elghozi J.L., et al. The sympathetic nervous system and the metabolic syndrome. J Hypertens 25 (2007) 909-920
70. Ness K.K., Hudson M.M., Ginsberg J.P., et al. Physical performance limitations in the Childhood Cancer Survivor Study cohort. J Clin Oncol 27 (2009) 2382-2389
71. Herman D.R., Ganz P.A., Petersen L., and Greendale G.A. Obesity and cardiovascular risk factors in younger breast cancer survivors: the Cancer and Menopause Study (CAMS). Breast Cancer Res Treat 93 (2005) 13-23
72. Thorsen L., Nystad W., Dahl O., et al. The level of physical activity in long-term survivors of testicular cancer. Eur J Cancer 39 (2003) 1216-1221
73. Hooning M.J., Botma A., Aleman B.M.P., et al. Long-term risk of cardiovascular disease in 10-year survivors of breast cancer. J Natl Cancer Inst 99 (2007) 365-375
74. Heikens J., Ubbink M.C., van der Pal H.P.J., et al. Long term survivors of childhood brain cancer have an increased risk for cardiovascular disease. Cancer 88 (2000) 2116-2121
75. Adams M.J., and Lipshultz S.E. Pathophysiology of anthracycline- and radiation-associated cardiomyopathies: implications for screening and prevention. Pediatr Blood Cancer 44 (2005) 600-606
76. Grundy S.M. Drug therapy of the metabolic syndrome: minimizing the emerging crisis in polypharmacy. Nat Rev Drug Discov 5 (2006) 295-309
77. Krentz A.J., Patel M.B., and Bailey C.J. New drugs for type 2 diabetes mellitus: what is their place in therapy?. Drugs 68 (2008) 2131-2162
78. Mekala K.C., and Tritos N.A. Effects of recombinant human growth hormone therapy in obesity in adults: a metaanalysis. J Clin Endocrinol Metab 94 (2009) 130-137
79. Howell S.J., Radford J.A., Adams J.E., Smets E., Warburton R., and Shalet S.M. Randomized placebo-controlled trial of testosterone replacement in men with mild Leydig cell insufficiency following cytotoxic chemotherapy. Clin Endocrinol 55 (2001) 315-324
80. Lusis A.J., Attie A.D., and Reue K. Metabolic syndrome: from epidemiology to systems biology. Nat Rev Genet 9 (2008) 819-830
81. Ross J.A., Oeffinger K.C., Davies S.M., et al. Genetic variation in the leptin receptor gene and obesity in survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study. J Clin Oncol 22 (2004) 3558-3562
82. Zitzmann M., Gromoll J., von Eckardstein A., and Nieschlag E. The CAG repeat polymorphism in the androgen receptor gene modulates body fat mass and serum concentrations of leptin and insulin in men. Diabetologia 46 (2003) 31-39
83. Skjaerpe P.A., Giwercman Y.L., Giwercman A., and Svartberg J. Androgen receptor gene polymorphism and the metabolic syndrome in 60-80 years old Norwegian men. Int J Androl (2008) 10.1111/j.1365-2605.2008.00942.x published online Dec 16.
84. Children's Oncology Group. Long-term follow-up guidelines for survivors of childhood, adolescent and young adult cancers, Version 3.0 (2008), Children's Oncology Group, Arcadia, CA
85. Blaauwbroek R., Tuinier W., Meyboom-de Jong B., Kamps W.A., and Postma A. Shared care by paediatric oncologists and family doctors for long-term follow-up of adult childhood cancer survivors: a pilot study. Lancet Oncol 9 (2008) 232-238
86. Robison L.L., Armstrong G.T., Boice J.D., et al. The Childhood Cancer Survivor Study: a National Cancer Institute-supported resource for outcome and intervention research. J Clin Oncol 27 (2009) 2308-2318